-

08:54:30 PM

PBYI Stock News

PBYI - Puma Biotechnology Inc

09/21/21 4:10 PM

Nasdaq : PBYI

conferences

Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference

Puma Biotechnology, Inc., a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 8:00 a.m. EDT on Tuesday, September 28, at the 2021 Cantor Virtual Global Healthcare Conference. Puma Biotechnology, Inc. is a biopharmaceutical company with a focus...

RHEA-AI

neutral

09/07/21 5:30 PM

Nasdaq : PBYI

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on September 1, 2021, the Compensation Committee of Puma’ s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 16,375 shares of Puma common stock to three new non-executive employees. Puma Biotechnology, Inc. is a biopharmaceutical...

RHEA-AI

very positive

09/07/21 4:15 PM

Nasdaq : PBYI

conferences

Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Puma Biotechnology, Inc., a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the virtual H.C. Wainwright 23 rd Annual Global Investment Conference, which will be held September 13-15, 2021. Puma Biotechnology, Inc. is a biopharmaceutical...

RHEA-AI

neutral

08/06/21 4:50 PM

Nasdaq : PBYI

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 2, 2021 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 15,938 shares of Puma common stock to three new

RHEA-AI

very positive

08/05/21 4:07 PM

Nasdaq : PBYI

earnings

Puma Biotechnology Reports Second Quarter 2021 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2021. Unless otherwise stated, all comparisons are for the second quarter of 2021 compared to the second quarter of 2020.Product revenue, net consists entirely

RHEA-AI

neutral

07/26/21 8:33 AM

Nasdaq : PBYI

Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has entered into a note purchase agreement with a fund of Athyrium Capital Management, LP, a specialized asset management company focused on opportunities in the global healthcare sector, for the issuance of up

RHEA-AI

very positive

07/22/21 4:15 PM

Nasdaq : PBYI

conferencesearnings

Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, Aug. 5, 2021, following the release of its second quarter 2021 financial results.The call may be accessed by dialing 1-877-709-8150 (domestic) or

RHEA-AI

neutral

07/02/21 5:15 PM

Nasdaq : PBYI

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2021, the Compensation Committee (the “Compensation Committee”) of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 34,375 shares of Puma

RHEA-AI

very positive

07/01/21 8:35 AM

Nasdaq : PBYI

fda approval

FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved a labeling supplement to the U.S. Prescribing Information for NERLYNX® that incorporates the use of NERLYNX dose escalation as evaluated in the Phase II CONTROL

RHEA-AI

neutral

06/04/21 5:30 PM

Nasdaq : PBYI

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 30,375 shares of Puma common stock to five new

RHEA-AI

very positive

PBYI Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.pumabiotechnology.com
Security namePuma Biotechnology Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees267
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing

PBYI Description:

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.